van Nederpelt, David R. http://orcid.org/0000-0003-0083-5238
Amiri, Houshang
Brouwer, Iman
Noteboom, Samantha
Mokkink, Lidwine B.
Barkhof, Frederik
Vrenken, Hugo
Kuijer, Joost P. A.
Article History
Received: 4 April 2023
Accepted: 20 June 2023
First Online: 1 August 2023
Declarations
:
: D.R. van Nederpelt: has nothing to disclose. H. Amiri: has nothing to disclose. I. Brouwer: has received research support from Merck, Novartis, Teva, and the Dutch MS Research Foundation. S. Noteboom is supported by research grants from Atara, Biotherapeutics, Merck and Biogen. L.B. Mokkink: has nothing to disclose. F. Barkhof serves on the steering committee or iDMC member for Biogen, Merck, Roche, EISAI and Prothena. Consultant for Roche, Biogen, Merck, IXICO, Jansen, Combinostics. Research agreements with Merck, Biogen, GE Healthcare, Roche. Co-founder and shareholder of Queen Square Analytics LTD. Supported by the NIHR biomedical research center at UCLH. H. Vrenken has received research support from Merck, Novartis, Pfizer, and Teva, consulting fees from Merck, and speaker honoraria from Novartis; all funds were paid to his institution. J.P.A. Kuijer has nothing disclose.
: The institutional review board approved the study protocol (NL555598.029.15) and written informed consent was obtained from all individuals, according to the Declaration of Helsinki.